Hyperfine, Inc. (HYPR)
NASDAQ: HYPR · Real-Time Price · USD
1.120
+0.010 (0.90%)
At close: Apr 8, 2026, 4:00 PM EDT
1.130
+0.010 (0.89%)
Pre-market: Apr 9, 2026, 8:30 AM EDT
Hyperfine Revenue
In the year 2025, Hyperfine had annual revenue of $13.56M with 5.22% growth. Hyperfine had revenue of $5.29M in the quarter ending December 31, 2025, with 128.05% growth.
Revenue (ttm)
$13.56M
Revenue Growth
+5.22%
P/S Ratio
8.09
Revenue / Employee
$132,971
Employees
102
Market Cap
109.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.56M | 673.00K | 5.22% |
| Dec 31, 2024 | 12.89M | 1.86M | 16.84% |
| Dec 31, 2023 | 11.03M | 4.22M | 61.90% |
| Dec 31, 2022 | 6.81M | 5.32M | 355.48% |
| Dec 31, 2021 | 1.50M | 1.20M | 408.84% |
| Dec 31, 2020 | 294.00K | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Treace Medical Concepts | 212.69M |
| Neuronetics | 149.16M |
| Owlet | 105.71M |
| AVITA Medical | 71.61M |
| SANUWAVE Health | 44.05M |
| Rapid Micro Biosystems | 33.59M |
| MaxCyte | 33.03M |
| QT Imaging Holdings | 18.93M |
HYPR News
- 42 minutes ago - Hyperfine Receives CE and UKCA Marks for Next-Generation Swoop® System and Latest Advancement in Optive AI™ Software - Business Wire
- 17 days ago - Horizon Technology Finance Provides $40 Million Loan Facility to Hyperfine - Business Wire
- 21 days ago - Hyperfine, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 weeks ago - Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 - Business Wire
- 2 months ago - Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System's Enhanced Stroke Detection Capabilities - Business Wire
- 2 months ago - Hyperfine Announces NEURO PMR Study Results Showing High Diagnostic Value and Superior Patient Experience in Neurology Clinics - Business Wire
- 2 months ago - Hyperfine Announces Enrollment of First Patient in Study to Expand Intended Use of the Swoop® System with Contrast Agents - Business Wire
- 3 months ago - Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results - Business Wire